TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from XBiotech ( (XBIT) ).
John Simard, President and CEO of XBiotech, announced his retirement effective December 8, 2025, after 21 years of leadership, but will remain as Chairman of the Board and continue to support the company in a consulting role. Sushma Shivaswamy, the Chief Scientific Officer since 2017, has been appointed interim CEO, with an increased annual salary of $750,000, as the company transitions to find a permanent CEO.
More about XBiotech
XBiotech, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is known for its innovative approach to treating diseases with its True Human™ antibodies, which are derived from natural human immune responses.
Average Trading Volume: 105,889
Technical Sentiment Signal: Sell
Current Market Cap: $75.61M
Find detailed analytics on XBIT stock on TipRanks’ Stock Analysis page.